3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
8
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
7
Folfox protocol
6
pembrolizumab
5
Drug Therapy
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
fludarabine
3
XELOX
3
Specimen Handling
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
toripalimab
2
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
Interleukin-2
×
Clear all
NCT06530303
2024-11-05
BAH248
Essen Biotech
Phase 1/2
Recruiting
85 enrolled